Immuno-based therapeutic strategies for initial unresectable locally advanced non-small cell lung cancer: a case report
Immuno-based therapeutic strategies for initial unresectable locally advanced non-small cell lung cancer: a case report
复制标题
初始不可切除的局部晚期非小细胞肺癌的免疫治疗策略：病例报告
DOI：
10.21037/tlcr-20-517
复制
发表时间：
2020-06-01
影响因子：
4
通讯作者：
Luo, Qingquan
中科院分区：
文献类型：
--
作者：
Jiang, Long;Huang, Jia;Luo, Qingquan
肺癌是全球癌症相关死亡的主要原因。即使对于接受多维治疗的患者，局部晚期肺癌的预后也很差。新辅助免疫疗法在许多类型的癌症，特别是肺癌中的结果令人鼓舞。然而，最初不可切除的非小细胞肺癌（NSCLC）伴T4或巨大肿胀N2淋巴结的患者的预后仍不令人满意，迫切需要新的治疗方式。在这里，我们提出了一个病人的情况下，最初不可切除的非小细胞肺癌与T4和庞大的肿胀N2淋巴结，并提出新辅助免疫为基础的治疗策略作为一个合理的选择，这样的患者的论点。
Lung cancer is the leading global cause of cancer-related deaths. Even for patients who receive multidimensional treatment, the prognosis for locally advanced lung cancer is poor. The outcomes of neoadjuvant immunotherapy have been encouraging in many types of cancer, and especially lung cancer. However, the prognoses of patients with initially unresectable non-small cell lung cancer (NSCLC) with T4 or bulky swollen N2 lymph nodes are still unsatisfying, and novel therapeutic modalities are desperately needed. Here, we present a case of a patient with initially unresectable NSCLC with T4 and bulky swollen N2 lymph nodes, and present the argument for neoadjuvant immuno-based therapeutic strategies as a reasonable option for such patients.